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Doxorubicin (Dox) treatment is limited by severe toxicity and frequent episodes of treatment failure. To minimize
adverse events and improve drug delivery efficiently and specifically in cancer cells, encapsulation of Dox with
naturally obtained galactoxyloglucan polysaccharide (PST001), isolated from Tamarindus indica was attempted.
Thus formed PST-Dox nanoparticles induced apoptosis and exhibited significant cytotoxicity in murine ascites cell
lines, Dalton’s lymphoma ascites and Ehrlich’s ascites carcinoma. The mechanism contributing to the augmented
cytotoxicity of nanoconjugates at lower doses was validated by measuring the Dox intracellular uptake in human
colon, leukemic and breast cancer cell lines. PST-Dox nanoparticles showed rapid internalization of Dox into
cancer cells within a short period of incubation. Further, in vivo efficacy was tested in comparison to the parent
counterparts - PST001 and Dox, in ascites and solid tumor syngraft mice models. Treatment of ascites tumors with
PST-Dox nanoparticles significantly reduced the tumor volume, viable tumor cell count, and increased survival and
percentage life span in the early, established and prophylactic phases of the disease. Administration of
nanoparticles through intratumoral route delivered more robust antitumor response than the intraperitoneal route
in solid malignancies. Thus, the results indicate that PST-Dox nanoparticles have greater potential compared to the
Dox as targeted drug delivery nanocarriers for loco regional cancer chemotherapy applications.
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Drug-induced toxicity is a serious problem affecting patients
undergoing chemotherapy. Depending on the toxicity profiles of
individual drugs, therapeutic index may be limited, resulting in higher
rate of treatment failures [1]. Apart from toxicity, cancer cells also
acquire self-remedial escape mechanisms such as drug efflux pumps or
increased drug metabolisms devouring attack from chemotherapy,
resulting in the chemoresistance [2].
Doxorubicin (Dox) is a common chemotherapeutic drug with wide
spectrum of anticancer activity against several malignancies. But, the
most common side-effects associated with anthracycline analogues
like Dox include acute and chronic toxicities such as myelosuppres-
sion, cardiomyopathies and congestive cardiac failure [3,4]. Toovercome these side-effects, integrated approaches utilizing combi-
nation therapies with cytotoxic, chemosensitizing and nanoparticle
agents have been devised. Encapsulation of Dox in the form of
PEGylated liposomes (Doxil) and Abraxane have increased the
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with hydrophilic polymers was found to increase cytotoxicity by
‘enhanced permeation and retention’ (EPR) relative to free
doxorubicin [6]. EPR effect enabled polymeric-drug nanoparticles
to enhance their diffusion rate, and thus accumulate within tumor
tissues than normal tissues, leading to enhanced antitumor efficacy
and reduced side-effects. A small number of advanced drug delivery
systems for Dox have been approved by the FDA for the treatment of
ovarian cancer and Kaposi's sarcoma which are in clinical use in the
United States [7]. Still, there are substantial challenges like high
treatment failure rates, unpredictable disease outcome, and tumor
recurrence apart from toxicity, while using any single-agent drugs.
In this scenario, naturally obtained polymeric nanoparticles are
important where they are utilized for the diagnosis and treatment of a
wide range of diseases including cancer. In the purlieu of cancer
therapeutics, polymeric nanoparticles are considered as novice drug
systems. But, in fact they are credible tumor targeting agents because
of their ability to sustain the conjugated drugs in circulation and
retain enhanced drug uptake via enhanced permeation and retention
effect [8–10]. They could be easily surface engineered to function
precisely over different types of architecture, shape, size, surface
charges across all the barriers for the optimal drug delivery [11,12].
However, strategies to co-encapsulate multiple drugs during the
synthesis of nanoparticles are always challenging. Physical loading,
chemical conjugation and covalent linkage of the drugs to the
polymer backbone has often been the method of choices [13–16].
But, several other factors such as steric hindrance, heterogeneity
and variable drug reactions interfere, and pose a major challenge
during synthesis [17]. Majority of the polymeric nanoparticles
are polymeric micelles which are electrically neutral, capable of
evading drug clearance by the reticulo-endothelial systems, and are
frequently used against murine solid tumors [18]. In combination
with Dox, they appear effective and safe [19]. Apart from being
biocompatible, polymeric nanocarriers also demonstrate favorable
pharmacokinetics [20].
We previously isolated and characterized naturally obtained
PST001 (Galactoxyloglucan) from the seed kernels of Tamarindus
indica (Ti) [21]. PST001 has been demonstrated to show excellent
antitumor and immunomodulatory activity against various cancers in
vitro and in vivo [21–23]. Another nanoparticle formulation of
PST001 and gold (PST-Gold) developed in our laboratory
demonstrated superior cytotoxic and immunomodulatory activity
compared to the parent polysaccharide [24,25]. PST001 in
conjugation with Dox also elicited significant anticancer activity
in breast, leukemic and colon cancer cells in vitro [26]. However, in
order to determine the versatile nature of this nanoconjugate
anticancer drug in aggressive cancers like lymphoma, current study
was aimed to evaluate the potential of PST-Dox in murine ascites and
solid tumors. In addition, the most effective drug delivery routes of
this nanoparticle derivative and the rate of Dox internalization from
the nanoparticle conjugates in the human breast, leukemic and colon
tumor sites were also determined. For this purpose, we synthesized
and chemically characterized nanoparticle conjugated PST001 and
Dox (PST-Dox), and tested its anti-tumor activity in vitro and in
vivo. Our results suggest that the PST-Dox exhibited excellent
cytotoxicity, apoptotic and antitumor activities in either forms of
ascites tumors. Specifically, nanoconjugates decreased tumor volume,
viable tumor cell counts, and increased overall survival in mice during
the early as well as established stages of the disease. Further, ourstudies also demonstrate that intratumoral nanoparticle drug delivery
is an effective choice over intraperitoneal route in combating
aggressive solid malignancies.
Materials and Methods
Modification of Doxorubicin and Characterization of PST-
Dox Nanoparticles
Ripened seeds of Ti were obtained from reliable sources. The seeds
were dried and powdered, and the polysaccharide, PST001 was
isolated as previously reported [21,23,24]. The carbohydrate content
was determined by Duboi’s method [27] using D-glucose as the
standard. The PST-Dox nanoparticles were prepared by ionic gelation
of PST001 and Dox using sodium tripolyphosphate (TPP) and the
final product was lyophilized and stored at 4°C until use. All
procedures were performed with minimal exposure to light.
Cell Lines
The murine lymphoid cancer cell lines Dalton’s lymphoma ascites
(DLA) and Ehrlich ascites carcinoma (EAC) were procured from
Amala Cancer Research Centre, Thrissur, India. Both DLA and EAC
cell lines were maintained in the peritoneal cavity of mice by
intraperitoneal serial transplantation of 1×106 cells/mice. The human
cancer cell lines MCF-7 (breast cancer) and K562 (leukemia) were
obtained from the National Centre for Cell Sciences, Pune, India. The
colon cancer cell line HCT116 was generously provided by the RGCB
(Rajiv Gandhi Centre for Biotechnology), Thiruvananthapuram,
India. The cells were maintained in DMEM media with 10% fetal
bovine serum and 5% CO2 at 37°C.
In Vitro Cytotoxicity Assay
The growth inhibitory capacity of the PST-Dox nanoparticles on
murine cancer cell lines, DLA and EAC cells were evaluated by MTT
(3-[4, 5-dimethylthiazol-2yl]-2, 5 diphenyltetrazolium) assay [28].
The absorbance was measured at 570 nm using a microplate
spectrophotometer (BioTek, Power Wave XS). MTT assays were
performed on cancer cell lines upon treatment with PST001, PST-
Dox nanoparticles and Dox with varying concentrations ranging from
0.0001 ng/ml to 100 μg/ml over a period of 24 to 48 hours.
Acridine Orange-Ethidium Bromide Double Staining Assay
Acridine orange-ethidium bromide double staining assay is a rapid
and inexpensive assay to detect apoptotic damages, based on the
differential uptake of two fluorescent DNA binding dyes by viable
and nonviable cells [29]. Briefly, control or PST-Dox treated DLA
and EAC cells were treated for 24 hours and double-stained with
acridine orange and ethidium bromide. The changes in fluorescence
in these cells were observed under an inverted fluorescent microscope
using a FITC filter (Olympus 1X51, Singapore).
Quantification of Cellular Uptake and Retention of Dox
Estimation of cellular uptake of Dox in human cancer cell lines,
HCT116, MCF7 and K562 was performed as described elsewhere
[30,31] with slight modifications. Briefly, cells were plated onto 12-
well plates at 105 cells/well and incubated in a 5% CO2 incubator at
37°C. When the cells attained confluence, they were treated with
vehicle or PST-Dox or Dox, and incubated for 4 h, trypsinized and
washed with ice-cold phosphate buffered saline (PBS, pH 7.4). Pellets
were lysed again with PBS containing 1%Triton-X accompanied with
rigorous vortexing. The supernatant collected were centrifuged at
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was measured in a fluorometer (FLx800, BioTek) at an excitation
wavelength of 485 nm and an emission wavelength of 590 nm. Results
are expressed as micrograms of Dox per milligrams of cellular protein.
Protein concentration of the cell lysates was determined using
Coomassie plus protein assay reagent and bovine serum albumin as
standards (Pierce, Rockford, IL, USA).
Visualization of Cellular Dox Uptake by Confocal Microscopy
Confocal fluorescence microscopy was used to observe the
intracellular uptake and distribution of Dox from PST-Dox nanopar-
ticles and the standardDox. Adherent cancer cells (HCT116 andMCF-
7) were grown overnight in 12 mm circular glass coverslips with 10 %
DMEMfor 24 hours. Cells were incubated with PST-Dox nanoparticles
(1 μg/ml) for 2 h and 6 h or Dox (1μg/ml) for 6 h. The cells in the cover
slips were fixed with 4% paraformaldehyde, counterstained with DAPI
and mounted with DPX on a clean glass slide. Slides were observed
under a fluorescence confocal microscope (NIKON A1R, USA) and
were analyzed using NIS Elements software. The confocal microscopy
settings were kept the same between samples. Doxorubicin excitation
and emission occurred at 485 nm and 595 nm whereas for DAPI,
excitation and emission occurred at 405 nm and 450 nm respectively.
Images were acquired in 60x optical zoom (Plan Apo VC 60x Oil DIC
N2 DIC N2).
Experimental Design for Ascites Tumors In Vivo
Female BALB/c mice were maintained in well-ventilated cages with
free access to normal mouse food and water provided ad libitum.
Temperature (25 ± 2°C) and humidity (50± 5%) was regulated and the
illumination cycle was set to 12 h light/dark. Animal protocols were
reviewed and approved by Institutional Animal Ethics Committee
(IAEC) and Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA), India and the experiments were
performed as summarized in Figure 1. Briefly, animals were divided into
four groups. All groups hadmice inoculated with either DLA or EAC on
Day 1, except for group 4, where the cells were injected on Day 8.Figure 1. Schematic for in vivoDLA and EAC ascites tumormodels.
Female mice were intraperitoneally transplanted with DLA or EAC
ascites tumors on day 1 or day 8 and divided into four groups as
shown, depending on the treatment schedule. Each of these
groups has been subdivided into four subgroups (n = 6/subgroup)
– Control (PBS), PST001, Dox and PST-Dox. Compounds were
administered on different days as shown. Mice were sacrificed to
estimate antitumor parameters on day 16 (group 1 and 2) or day 23
(group 3 and 4).Group 1 was treated only once (day 2) with compounds. In group 2,
compounds were administered on days 2 to 15. Group 3 had
compounds administered on days 9 to 22.Group 4 received prophylactic
treatment of compounds from day 1 to 7. Each of these groups had four
treatment protocols – PBS (vehicle or control), PST001 (100 mg/kg),
PST-Dox nanoparticles (2.25 mg/kg) and Dox (2.25 mg/kg) under
subgroups (n = 12/sub group). Six animals from the group were used for
survival analysis. Vehicle and the compounds were administered once
daily by intraperitoneal (i.p.) injection. The mean survival time and
percentage of increment in life span (% ILS) was calculated as previously
reported [25,32].
EAC-Induced Solid-Tumor Mice Syngraft In Vivo
EACcells (1×106 cells) were injected subcutaneouslywith a fine needle
(31G) to develop solid tumors in the hind limb of mice (n = 6/group).
These experiments utilized administration of compounds - PST001,
PST-Dox nanoparticles and Dox by two different routes, intraperitoneal
(i.p.) and intratumoral (i.t.) injections, daily for 14 consecutive days,
starting on day 9 after tumor inoculation (days 9 to 22 as shown in
Figure 1, Group 3). Animals were sacrificed on day 23 to determine
tumor volume and overall survival (n = 6/subgroup). The radii of the
developing tumors were measured every third day from day 7 to day 31,
using vernier calipers and the tumor volume was estimated using the
formula: V = 4/3πr1
2r2, where r1 and r2 represent the radii from two
different sites [25,32,33].
Statistical Analysis
Data are expressed as the mean ± standard deviation (SD) of three
replicates and analyzed using GraphPad PRISM software 5.0
(GraphPad Software Inc., San Diego, CA). One-way analysis of
variance was used for the repeated measurements, and the differences
were considered to be statistically significant if P b .05. SPSS 17.0
statistical software (IBM Inc., NY) was used for Kaplan-Meier
survival analysis. The IC50 values were calculated using the Easy Plot
software (Spiral Software, MD).Results and Discussion
Synthesis and Cytotoxic Effects of PST-Dox Nanoparticles
The polysaccharide PST001 isolated from the seed kernels of Ti was
found to have neutral pH with total sugar content of 98%, as
determined by the phenol-sulfuric acid method. After isolation, the
polysaccharide was purified by gel filtration chromatography,
lyophilized and stored at 4°C. Ionic gelation was utilized to produce
the PST-Dox nanoparticles with an average size of 10 nm;
nanoconjugates were lyophilized and stored with minimal exposure
to light [26]. PST-Dox nanoparticles were evaluated for cytotoxic
activity against two murine ascites cancer cell lines, DLA and EAC by
MTT assay. The cytotoxic potential was found to be highly significant
in both the cell lines examined (Figure 2A and B). DLA and EAC cells
were growth-arrested with IC50 values of 0.58 ± 0.4 μg/ml and 0.42 ±
0.3 μg/ml, respectively after 24 hours of incubation with PST-Dox
nanoparticles. Dox alone generated IC50 values of 6.37 ± 1.2 μg/ml
(DLA) at 48 h, and 80 ± 1.4 μg/ml (EAC) at 24 hours. The native
polysaccharide PST001 produced IC50 values of 43 ± 1.3 μg/ml
(DLA) and 597 ± μg/ml (EAC) only after prolonged hours (48 h) of
incubation (Figure 2, A and B). Earlier, we showed the potency of
PST-Dox against other cancer cell lines such as MCF-7, HCT116 and
K562 cells [26].
Figure 2. Evaluation of cytotoxicity and apoptosis in PST-Dox nanoparticles treated DLA and EAC cells.Inhibition of cell proliferation rates
were determined by MTT assay at 24 hours for (a) DLA and (b) EAC cells. Results were expressed as the mean ± SD from three
independent experiments. Representative fluorescent images of apoptosis evaluation of cell lines treated with vehicle (PBS) or 1 μg/ml
PST-Dox nanoparticles for 24 hours by (c) Acridine Orange- Ethidium Bromide dual staining in DLA and EAC cells. Phase contrast
microscopy images are shown in (d) DLA and EAC cells treated with vehicle or PST-Dox nanoparticles.
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new Dox formulation with PST001, PST-Dox also exhibits wide
spectrum of anticancer activity with even better effects than PST001
or Dox as single agents alone. This could be partly due to the
cytotoxic effects elicited by the already known cytotoxic agents,
PST001 and Dox. In addition to the synergistic effect, the increased
surface-to-volume ratio of the nanoparticles permitted PST-Dox with
optimal physical, chemical, and biological activities compared with its
parent macromolecules. Further, the synthesis of PST-Dox involves
the polyanion, TPP as the linker. PST001 being neutrally charged
and consisting of numerous hydroxyl groups provide anchors for
drug attachment and modification. This enables easy binding with
TPP, and further with the positively charged Dox-HCl. This
nanoconjugate was previously tested to provide a Dox-encapsulation
efficiency of 70% as reported [26]. The release profile of Dox fromthe PST-Dox nanoparticles and Dox-HCl at different pH levels over
time at ambient temperature was also previously evaluated [26]. It was
found that doxorubicin hydrochloride showed a burst release within
3–5 hours regardless of the change in pH from 4.5 to 7.4. However,
the PST-Dox nanoparticle showed excellent pH and time dependent
Dox release kinetics. Yet, another nanoformulation of PST001 with
gold (PST-Gold) also demonstrated similar kinetic profiles and
exhibited superior anticancer potential [24].
PST-Dox Nanoparticles Exert Anticancer Effects Through the
Induction of Apoptosis
To determine the mechanism of cell death induced by the PST-
Dox nanoparticles in cancer cells, apoptotic assays were conducted
after the administration of 1 μg/ml of nanoparticles for 24 hours.
Compared to the controls, acridine orange-ethidium bromide
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drastic change in fluorescence from green to yellow/red that was
associated with other apoptotic features such as the presence of
apoptotic bodies and nuclear condensation. Significant changes in
fluorescence were observed in both DLA and EAC cells upon
treatment with PST-Dox nanoparticles (Figure 2C). Morphological
and phase contrast microscopy evaluation of cells treated with PST-
Dox nanoparticles (1 μg/ml) for 24 hours showed salient features of
apoptosis such as distorted shape, membrane blebbing, and the
presence of apoptotic bodies compared to the vehicle in DLA and
EAC cells (Figure 2D).
Apoptosis is the most appropriate mode of cell death in living
systems induced by several polysaccharides [34], anticancer drugs
such as doxorubicin [35] and polysaccharide based nanoparticles [24].
Membrane blebbing, one of the hallmarks of apoptosis refers to the
irregular bulges in the plasma membrane of the cells caused by
localized decoupling of the cytoskeleton from the plasma membrane.
PST-Dox also exhibited similar trends of apoptosis in MCF-7, K562
and HCT116 as reported earlier [26]. In the current study, the
inhibition of cell proliferation exhibited by the PST-Dox nanopar-
ticles in the lymphoma was confirmed through the induction of
apoptosis. The extended efficiency of the PST-Dox nanoparticle
compared to PST001 and Dox in inducing apoptosis may have been
due to the increased uptake of the particles via endocytosis because of
small size and increased surface-to-volume ratio [36].Figure 3. Intracellular doxorubicin uptake by human cancer cells.Conf
uptake and distribution of Dox in (a) HCT116 and (b) MCF-7 cells. R
standard clinically used Dox (1μg/ml at 4 h) or PST-Dox nanoparticles
represents the phase contrast microscopy images and the consecut
images (c) Quantitation of Dox uptake in HCT116, MCF-7 and K562 c
485 nm and an emission wavelength of 590 nm in the presence of e
significant differences at a, pb0.001 compared to corresponding conDox is Internalized Efficiently From PST-Dox Nanoparticles
in Human Cancer Cells
Although DLA and EAC models exhibited robust anticancer effects,
cellular uptake and retention assays were not possible in ascites tumors
as per the standardized protocols. However, it was relevant to evaluate
the internalization of Dox from the nanoconjugates in clinically
applicable human cancer cells. Hence, an established protocol
mimicking clinical scenario in human cancer cell lines such as
HCT116, MCF-7 and K562 was utilized for the measurement of
intracellular Dox. Intracellular incorporation of Dox measured in
HCT116 (Figure 3A) andMCF-7 (Figure 3B) by confocal fluorescence
microscopy revealed a significant and visible increase in the doxorubicin
uptake in the nanoparticle treated cells compared with naked Dox.
There occurred a time dependent increase in the doxorubicin
fluorescence with PST-Dox nanoparticles, where 6 hours of adminis-
tration showed more visible internalization than at 2 hours in all the
three cell lines examined. However, 2 h of incubation with PST-Dox
nanoparticles showedmore fluorescence than nakedDox for 6 h in both
HCT116 andMCF-7 cells. Vehicle-treated cells showedwell integrated
nucleus with the DAPI staining in all the cells. Distortion of the nuclear
material was observed on administration of both Dox and PST-Dox
nanoparticles, indicating the cytotoxic effect on cancer cells. Quanti-
fication of the cellular Dox uptake by fluorimetric estimation of
HCT116 and MCF-7 cell lines treated with 1 μg/ml of either Dox or
PST-Dox nanoparticles for 4 hours revealed a significant increase inocal fluorescence microscopy was used to evaluate the intracellular
epresentative images of these cells treated with vehicle (control),
(1 μg/ml) at 2 h (second to last row) or 6 h (last row). First column
ive columns represent DAPI, Dox, DAPI+Dox overlay and merged
ells was determined fluorimetrically at an excitation wavelength of
ither Dox (1 μg/ml) or PST-Dox nanoparticles (1 μg/ml). Statistically
trol group.
Figure 3. Continued.
530 Dox-galactoxyloglucan nanoparticles for in vitro and in vivo tumor targeting Joseph et al. Translational Oncology Vol. 7, No. 5, 2014Dox uptake from the nanoparticles when compared with the free drug,
Dox (Figure 3C). HCT116 cells showed the maximum Dox uptake of
61 ± 2.5 μg/mg cellular protein from the nanoparticles, while the native
Dox showed only 25 ± 1.3 μg/mg cellular protein. MCF-7 and K562
cells exhibited uptake of 44 ± 1.7μg and 24 ± 2.2μg of doxorubicin/mg
cellular protein respectively from the nanoparticles. However, relatively
lesser quantity of doxorubicin was internalized from the naked Dox;
26 ± 1 μg (MCF-7) and 20 ± 1.2 μg (K562) per mg of cellular protein
(Figure 3C).
The increased cytotoxicity observed with PST-Dox nanoparticles
than the native drug even at lower concentrations and lesser
incubation periods was evident through the increased uptake of the
nanoparticles by the cancer cells. PST-Dox nanoparticles showed a
rapid uptake into the cancer cells within a short period of incubation.
Conventionally, nanoconjugates of polymers release drugs in afavorable manner either via diffusion of the drug moieties through
the polymer matrix or via differential surface erosion rates of the
nanoparticles. The enhanced uptake of the PST-Dox nanoparticles
than the parental Dox by the cancer cells could be due to the EPR
effect exhibited by the nanoparticles by virtue of their increased
surface-to-volume ratio and small size [37].
Increased uptake visibly observed with the confocal microscopy
was consistent with the quantitation of fluorimetric estimation in all
the cancer cells. The favorable properties exhibited by PST-Dox
nanoparticles in terms of increased cancer specific cytotoxicity and
minimal toxicity towards normal cells could be attributed to the
higher intracellular accumulation and deeper penetration of the
nanoparticles into the cancer cells. Delivery of the anthracycline
doxorubicin in tumor cells was indeed sub-optimal in its unmodified
form due to its non-specific distribution in the untargeted regions,
Figure 4. Antitumor effects of parent compounds and nanoparticles in DLA mice.(a) Ascites tumor volume measurements were taken
from the different treatment groups/subgroups at the end of experimental period (b) Percentage increment in the life span in DLA mice
treated with various compounds. Results are expressed as themean± SD of the group. Statistically significant differences at a, P b .0001;
b, P b .001 and c, Pb0.01 compared to corresponding control group. (c) Kaplan-Meier survival curves of DLA-tumor mice treated with
different compounds in group 2, group 3, and group 4. Significance shown is for PST-Dox mice vs. corresponding control group.
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have previously reported the tumor-specific bioaccumulation of the
nanoparticles [26] and the current in vitro data presented here
establish that PST-Dox nanoparticles readily delivers Dox into the
human cancer cells as early as 2 h after administration, probably
owing to its small size compared with the clinically used analogue.PST-Dox Nanoparticles are Effective Against Early,
Established and Highly Recurrent Stages of Ascites Tumors
In spite of the robust efficacy exhibited by the PST-Dox in vitro,
we next evaluated antitumor effects in vivo in order to establish the
therapeutic utility. DLA and EAC ascites tumor-bearing mice were
evaluated on the 16th and 23rd day of the compound administration
Table 1. Assessment of antitumor parameters in group 2.
Parameter DLA EAC
Control PST001 Dox PST- Dox Control PST001 Dox PST- Dox
Tumor volume (ml) 10 ± 0.5 6 ± 0.3a 3.4 ± 0.3a 2.7 ± 0.3a 11 ± 1.0 5.5 ± 1.0a 3.4 ± 0.5a 3 ± 0.4a
Body weights (g) 33 ± 1.2 29 ± 1.1 22 ± 0.9a 29 ± 0.6 34 ± 0.7 30 ± 1.0 23 ± 1.3a 29 ± 0.8
TCC (106 cells/ml) 166 ± 2.1 88 ± 1.9a 56 ± 1.0a 44 ± 0.8a 175± 1.2 82 ± 0.8a 54 ± 0.7a 47 ± 1.0a
% VTCC (106 cells/ml) 95 ± 1.9 75 ± 0.9a 49 ± 0.6a 42 ± 1.0a 94 ± 1.0 72 ± 1.0a 45 ± 1.5a 43 ± 1.3a
MST (days) 21 ± 1.1 29 ± 1.9a 39 ± 1.4a 70 ± 1.0a 20 ± 1.0 27 ± 1.4a 35 ± 1.2a 68 ± 0.9a
% ILS 0.0 52 ± 1.7a 85.7 ± 1.2a 233 ± 1.9a 0.0 50 ± 1.0a 75 ± 1.4a 240 ± 1.8a
Evaluation of various parameters in mice injected with DLA or EAC cells on day 1 followed by compound administration on days 2 through 15 (group 2). Data are expressed as mean ± SD (n = 6). Statistically
significant differences at a, P b .001 compared to respective control group. TCC – Tumor cell count; VTCC – Viable tumor cell count; MST – Mean survival time, ILS – Increment in life span.
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tumor cell counts, and % ILS. Body weights were proportional to the
age in weeks demonstrating no significant differences except in mice
treated with Dox (Table 1 for group 2; for others data not shown).
Tumor reduction in DLA-bearing mice in terms of tumor volume was
evident in all the groups except group 1 in comparison to the control
group (Figure 4A; Table 1; Supplementary Tables 1 and 2). Tumor
reduction was highly significant in PST-Dox treated mice in group 2
(P b .0001), followed by group 4 (P b .001) and group 3 (P b .001) in
comparison to the control. Dox treatment also reduced DLA tumor
volume significantly in at least three groups (group 2, P b .0001; group
4, P b .001; group 3,P b .001 vs. control). Although PST001 as a single
agent was effective, reduction in tumor volume was significant only in
group 4 (P b .001) and group 2 (P b .001). As noted above, the
compounds failed to reduce the tumor volume significantly in group 1,
probably owing to a single day treatment regimen after tumor
inoculation. Likewise, as observed in tumor reduction, % ILS was also
highly significant in PST-Dox treated group 2, followed by group 3 and
group 4 (all three groups at P b .0001 vs. control) (Figure 4B; Table 1;
Supplementary Tables 1 and 2). Dox was also effective in increasing the
life span in group 2, group 3 and group 4 (all three groups at P b .001),
while PST001 was significant in group 4 and group 2 (P b .001).
However, it is significant to note that PST-Dox also increased the life
span in group 1 mice bearing DLA tumor (P b .01). The Kaplan-Meier
survival curves of DLA mice treated with PST001, Dox or PST-Dox
nanoparticles in different groups are shown in Figure 4C. PST-Dox
treated mice group was highly significant (P b .001 vs. control), followed
by Dox (P b .01) and PST001 (P b .01). Just as in the group 4, PST001
was slightly better than Dox with respect to the survival curves.
A similar trend showing tumor reduction was also seen in the EAC-
bearing mice in all groups except group 1 (Figure 5A; Table 1;
Supplementary Tables 1and 2). PST-Dox had the best effect compared
to other compounds in reducing EAC tumor in the majority of the
treatment regimen. Group 2 showed the highest effect (P b .0001) in
terms of tumor volume reduction, followed by group 3 (P b .001) and
group 4 (P b .001) compared to the respective control mice. Treatment
with Dox was also effective in group 2 (P b .0001), followed by group 4
(P b .001) and group 3 (P b .001). PST001 alone was the least effective
(P b .001 vs. respective control) among the three treatment groups
which showed some tumor reduction. In EAC-bearing tumor mice, a
maximum ILS of 240 ± 1.8% was observed on PST-Dox nanoparticle
administration in group 2 (Figure 5B; Table 1; Supplementary Tables 1
and 2). Increment in the lifespan was highly significant in PST-
Dox treated groups 2 and 3 (P b .0001 vs. control) followed by group 4
(P b .001 vs. control). ILS percent also corresponded with tumor
reduction in nanoparticle treated mice. Although not comparable
with PST-Dox, Dox also prolonged life span in groups 2, 3 and 4(P b .001 vs. control). As seen earlier, PST001 was the least
effective drug with ILS around 54% in group 4, followed by group
2 (both groups at P b .001 vs. control). Group 1 treatment
regimen did not have significant improvement with respect to ILS
in all the three drugs tested which is consistent with the tumor
reduction seen in EAC cells. The Kaplan-Meier survival curves of
EAC groups are shown in Figure 5C. PST-Dox treatment was
highly significant in groups 2, 3 and 4 compared to the
corresponding control group (P b .001). Like in the previous
data sets, Dox treatment (P b .01) was the next significant group,
followed by PST001 in the Kaplan-Meier survival curves.
In the ascites tumor models, it is clear that PST-Dox showed the
best overall effect, especially when administered for several days before
and after tumor inoculation. This points to the fact that PST-Dox is
indeed efficient against tumors those are recently transplanted (days
2–15), established (days 9–22) or have chances of recurrence (days 1–
7). In the clinical scenario, this is relevant because the drug could be
effective in early, established and resected stages of the disease.
Another aspect of this nanoconjugate is that they are a safer alternative
compared to the parental Dox. In our studies, PST-Dox nanoparticles
was found to be safer in animals with no indication of side-effects
during the entire course of experiments in both the DLA and EAC
ascites tumor models (Supplementary Figure 1). Even though Dox
administration was effective and reduced the tumor burden, it was
predominantly laden with visible signs of toxicity (Supplementary
Figure 1). Majority of the animals treated with Dox showed severe
weight loss, alopecia and cachexia, whereas PST-Dox treated mice
appeared normal with no apparent signs of toxicity.
Intratumorally Administered PST-Dox Nanoparticles are
More Efficient Against Solid Malignancies
We next evaluated the antitumor activity of PST-Dox nanopar-
ticles in a syngenic EAC-induced solid-tumor mice syngraft. There
was a significant reduction in the tumor burden observed as early as
day 13 (intratumoral) or day 16 (intraperitoneal), on different routes
of PST-Dox administration. Both i.p. (Figure 6A, Supplementary
Table 3) and i.t. (Figure 6B, Supplementary Table 3) routes
showed significant solid tumor reduction starting from days 13 or day
16 (P b .001 vs. respective control) on treatment with PST-Dox
nanoparticles. For the intratumoral drug treatment, statistical
significance (P b .001 vs. control) was achieved from day 19 (Dox)
and day 25 (PST001) for the parent compounds. For intra-
peritoneal drug treatment, solid tumor reduction was statistically
significant (P b .001 vs. control) from day 19 (Dox) and day 25
(PST001). As expected in the control group, the size of solid tumor
increased as the days progressed and the tumor burden was 3.7–5.6-
fold higher compared to the PST-Dox treated mice at the end of 31
Figure 5. Antitumor effects of parent compounds and nanoconjugates in EAC mice. (a) EAC ascites tumor volume was measured in
different treatment groups/subgroups at the end of experimental period (b) Percentage increment in the life span in EAC mice treated
with various compounds. Data are expressed as mean ± SD of all mice in the group. Statistically significant differences at a, P b .0001 and
b, P b .001 compared to corresponding control group. (c) Kaplan-Meier survival curves of EAC-tumor mice treated with PST001, Dox and
PST-Dox in groups 2, 3, and 4. Significance shown is for PST-Dox mice vs. respective control group.
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an ILS of 100 ± 1.8%, while PST001 and Dox yielded only 37.5 ±
2% and 66.6 ± 2.1% respectively. However, in the case of i.t.
administration, PST-Dox nanoparticles showed a peak ILS of 139 ±
1.8%, followed by 78.9 ± 1.9% (Dox) and 42 ± 2.1 % (PST001).The Kaplan-Meier survival curves for i.p. and i.t. modes of different
drugs in EAC solid tumor bearing mice are shown in Figure 6D.
Among the three drugs tested, it is obvious that PST-Dox
nanoparticles were the most efficient yielding a significant solid
tumor regression and increment in life span on i.t. administration
Figure 6. Efficacy of various compounds against EAC solid tumors in mice.EAC cells were injected subcutaneously in the hind limbs to
develop solid tumors inmice. Compoundswere injected either (a) intraperitoneally (i.p.) or (b) intratumorally (i.t.) for the entire duration of the
experiment. Solid-tumor measurements were taken every three days starting from day 7 until day 31 as shown. Statistical significance was
achieved for PST-Dox vs. control group from day 13 on intratumoral administration (P b .01) and from day 16 on intraperitoneal administration
(P b .01) (c) Increment in life span was calculated in EAC-induced solid-tumor bearing mice with respect to different routes of drug
administration. Results are expressed as the mean ± SD of the group. Statistically significant differences at a, P b .001 and b, P b 0.01
compared to the other route. (d) Kaplan-Meier survival curves of EAC-induced solid-tumor bearing mice administered with i.p. or i.t.
administration of PST001 or Dox or PST-Dox nanoparticles. Significance shown is for PST-Dox mice vs. respective control group.
534 Dox-galactoxyloglucan nanoparticles for in vitro and in vivo tumor targeting Joseph et al. Translational Oncology Vol. 7, No. 5, 2014compared to i.p. administration. As observed earlier, even in the solid
tumors, Dox treatment showed the second best overall effect,
followed by PST001. But, it is interesting to note that there were no
differences in the trends of tumor reduction between the parentcompounds, PST001 and Dox (Figure 6A vs. B) on either mode of
drug administration.
Ascites tumor is the direct nutritional source for tumor cells, and an
increased volume indicates the need to meet the nutritional
Translational Oncology Vol. 7, No. 5, 2014 Dox-galactoxyloglucan nanoparticles for in vitro and in vivo tumor targeting Joseph et al. 535requirements of growing tumor cells [39]. Evaluation of the
anticancer potential in mice models showed significant reduction in
the ascites tumor volume as evidenced in various experimental groups.
Treatment with PST-Dox nanoparticles significantly reduced the
tumor volume, viable tumor cell counts, and increased lifespan in
both the ascites and solid tumor models. The idea of delivering drugs
intratumorally has not been evaluated much in the area of carrier
based therapeutics. However, it results in the increased drug
concentration at the specific target sites while minimizing the local
toxicity [40,41]. Hence, an improvement in the therapeutic index is
expected. In our context, administration of nanoparticles via
intratumoral route delivered higher response than the intraperitoneal
route, but no such variation was observed in the case of PST001 and
Dox. This could be owing to the phenomenon of tumor leakage
exhibited by the bulk molecules. Although larger macromolecules
displayed the highest accumulation in tumors, they penetrated only a
relatively short distance into the tumor and were mostly concentrated
near the vascular surface [42]. It has been proposed that nanoparticles
demonstrated increased cytotoxicity by ‘enhanced permeation and
retention’ (EPR) relative to the parent polymer through which they
tend to be accumulated at the tumor sites, delivering better responses
with less deleterious effects. Importantly, tumor is accompanied with
acidosis and tumor microenvironment will follow a drastic drop in
pH compared with the surrounding niche. Hence, in the case of
hydrophilic polymers like PST001, EPR will enable the accumulation
of PST-Dox nanoparticles and release of Dox preferentially at the
tumor target sites. This aspect was noticed with the release kinetics
performed on human cancer cell lines such as HCT116, MCF-7 and
K562 for the measurement of intracellular Dox. Also, both the
confocal measurement and flurimetric estimation clearly demonstrate
the increased accumulation of Dox from the PST-Dox nanoparticles
compared to the naked Dox-Hcl.
Prolongation of lifespan in animals with an ILS exceeding 25%
indicated antitumor effectiveness of a drug as per NCI criteria [25]. The
tumor reduction exhibited by PST-Dox nanoparticle was higher than
the clinically used counterpart Dox, and the overall survival was also the
longest than many known chemotherapeutics. This superior effect
combined with less toxicity could be attributed to the already reported
immunomodulatory effects of PST001 [22] in the nanoparticle
formulation. Most chemotherapeutic agents have serious side-effects
which limit their widespread clinical applications, warranting the need
for anticancer agents that are non-toxic to normal cells. We recently
reported the tumor specificity and reduction in the Dox organ-related
toxicity in galactoxyloglucan-Dox conjugated nanoparticles [26]. In the
current study also, there were no observable side-effects upon
administration of the parent polysaccharide as well as its nanoparticle
derivative, which justifies their unique drug utility. PST-Dox
nanoparticles maintained the safety profile of the immunostimulatory
polysaccharide, PST001 while eliciting anticancer potential of both Dox
and PST001. Thus, our data suggests that PST-Dox nanoparticle is a
better alternative to the clinically available Dox in all the aspects, with
respect to limiting both solid and ascites tumors.
Conclusions
This study demonstrates the promising anticancer potential of a
nanoparticle aggregate of doxorubicin, PST-Dox. Galactoxyloglucan
nanoparticles carrying the Dox moiety significantly decreased cell
viability of murine ascites by the induction of apoptosis in the
monolayer culture. The cellular uptake of the PST-Dox also showedencouraging results in the colon and breast cancer cells compared to
the uptake from the free Dox. In the ascites tumors, PST-Dox
increased survival by reducing the tumor burden, especially in early,
later and prophylactic phases of ascites tumors. In particular, they
were very effective intratumorally against solid tumors. This indeed
will extend the drug utility of PST-Dox for more intensive loco
regional applications without causing any non-specific toxicity,
especially in the case of easily accessible solid malignancies. Agents
like PST-Dox deliver multiple effects at the local tumor sites without
any side-effects, and offer better flexibility for cancer treatment
optimization. Although higher animal models and more mechanistic
studies are warranted, PST-Dox has the potential to substantially
improve the therapeutic outcome in several malignancies as
evidenced. Hence, PST-Dox nanoparticles should be considered as
an alternative to Dox in the mainstream chemotherapy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2014.07.003.
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